(VIANEWS) – Equus Total Return (EQS), Iamgold Corporation Ordinary Shares (IAG), TG Therapeutics (TGTX) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Equus Total Return (EQS)
139.2% sales growth and 31.01% return on equity
Equus Total Return, Inc. is a business development company (BDC) specializing in leveraged buyouts, management buyouts, corporate partnerships/joint ventures, growth and expansion capital, acquisition financing, roll-up acquisition strategies, operational turnarounds, recapitalizations of existing businesses, special situations, equity and equity-oriented securities issued by privately owned companies, debt securities including subordinate debt, debt convertible into common or preferred stock, or debt combined with warrants and common and preferred stock, and preferred equity financing. It invests in small to mid-sized companies and acts as a lead investor. It invests in technology, telecommunication, financial services, natural resource and industrial manufacturing and services. It invests in companies engaged in the alternative energy, real estate, healthcare, education, e-learning, leisure and entertainment, and foreign investment sector in the United States, China, India, and Europe. It investments include common and preferred stock, debt convertible into common or preferred stock, debt combined with warrants and options, and other rights to acquire common or preferred stock. It seeks to invest in companies between $1 million to $25 million with revenues between $5 million and $150 million with EBITDA between $2 million to $50 million. It seeks to take control and non-control equity positions. Equus Total Return, Inc. was founded in 1991 and is based in Houston, Texas with additional office in Vancouver, Canada.
Earnings Per Share
As for profitability, Equus Total Return has a trailing twelve months EPS of $0.96.
PE Ratio
Equus Total Return has a trailing twelve months price to earnings ratio of 1.57. Meaning, the purchaser of the share is investing $1.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.01%.
2. Iamgold Corporation Ordinary Shares (IAG)
79% sales growth and 6.57% return on equity
IAMGOLD Corporation, through its subsidiaries, explores, develops, and operates gold mining properties in North America, South America, and West Africa. The company owns interests in the Rosebel mine located in Suriname, South America; the Essakane mine situated in Burkina Faso and Boto gold project located in Senegal, West Africa; and Westwood mine, covers an area of 1,925 hectare and located in Quebec and the Côté gold project, which covers an area of 586 square kilometer located in Ontario, Canada. Its exploration and development projects include the Pitangui project in Brazil; the Karita project located in Guinea; the Diakha-Siribaya project situated in Mali; and the Nelligan and Monster Lake projects located in Quebec, Canada. IAMGOLD Corporation was incorporated in 1990 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Iamgold Corporation Ordinary Shares has a trailing twelve months EPS of $0.29.
PE Ratio
Iamgold Corporation Ordinary Shares has a trailing twelve months price to earnings ratio of 14.1. Meaning, the purchaser of the share is investing $14.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.57%.
Volume
Today’s last reported volume for Iamgold Corporation Ordinary Shares is 9201840 which is 10.39% below its average volume of 10269400.
Revenue Growth
Year-on-year quarterly revenue growth grew by 49.8%, now sitting on 1.1B for the twelve trailing months.
Yearly Top and Bottom Value
Iamgold Corporation Ordinary Shares’s stock is valued at $4.09 at 01:22 EST, way under its 52-week high of $4.60 and way above its 52-week low of $1.99.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 700% and 300%, respectively.
3. TG Therapeutics (TGTX)
67.5% sales growth and 43.93% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.3.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 54.93. Meaning, the purchaser of the share is investing $54.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.93%.
Volume
Today’s last reported volume for TG Therapeutics is 3268640 which is 12.84% below its average volume of 3750430.
Revenue Growth
Year-on-year quarterly revenue growth grew by 713.5%, now sitting on 289.33M for the twelve trailing months.
4. Royal Caribbean Cruises (RCL)
17.9% sales growth and 50.68% return on equity
Royal Caribbean Cruises Ltd. operates as a cruise company worldwide. The company operates cruises under the Royal Caribbean International, Celebrity Cruises, and Silversea Cruises brands, which comprise a range of itineraries. As of February 21, 2024, it operated 65 ships. Royal Caribbean Cruises Ltd. was founded in 1968 and is headquartered in Miami, Florida.
Earnings Per Share
As for profitability, Royal Caribbean Cruises has a trailing twelve months EPS of $6.31.
PE Ratio
Royal Caribbean Cruises has a trailing twelve months price to earnings ratio of 20.23. Meaning, the purchaser of the share is investing $20.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 50.68%.
Moving Average
Royal Caribbean Cruises’s value is under its 50-day moving average of $137.44 and way above its 200-day moving average of $115.46.
Volume
Today’s last reported volume for Royal Caribbean Cruises is 2760970 which is 0.36% below its average volume of 2771210.
Previous days news about Royal Caribbean Cruises(RCL)
- According to Zacks on Wednesday, 29 May, "This calls for investing in solid consumer discretionary stocks such as PlayAGS, Inc. (AGS Quick QuoteAGS – Free Report) , Hasbro, Inc. (HAS Quick QuoteHAS – Free Report) , Lifetime Brands, Inc. (LCUT Quick QuoteLCUT – Free Report) , Royal Caribbean Cruises Ltd. "
- Zacks.com featured highlights include NVIDIA, Alphabet and royal caribbean cruises. According to Zacks on Wednesday, 29 May, "Chicago, IL - May 29, 2024 - Stocks in this week’s article are NVIDIA (NVDA Quick QuoteNVDA – Free Report) , Alphabet (GOOGL Quick QuoteGOOGL – Free Report) and Royal Caribbean Cruises (RCL Quick QuoteRCL – Free Report) .", "To that end, NVIDIA, Alphabet and Royal Caribbean Cruises have been selected as the top picks with a high net income ratio."
5. Agree Realty Corporation (ADC)
13.5% sales growth and 3.48% return on equity
Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of June 30, 2020, the Company owned and operated a portfolio of 936 properties, located in 46 states and containing approximately 18.4 million square feet of gross leasable area. The common stock of Agree Realty Corporation is listed on the New York Stock Exchange under the symbol "ADC".
Earnings Per Share
As for profitability, Agree Realty Corporation has a trailing twelve months EPS of $1.69.
PE Ratio
Agree Realty Corporation has a trailing twelve months price to earnings ratio of 35.09. Meaning, the purchaser of the share is investing $35.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
